Fucoidan Upregulates TLR4/CHOP-Mediated Caspase-3 and PARP Activation to Enhance Cisplatin-Induced Cytotoxicity in Human Lung Cancer Cells
In this study, we found that sequential therapy, i.e., cisplatin followed by fucoidan, reduced tumor volume in an LLC1-bearing C57BL/6 mouse model. Using a series of combined therapeutic experiments, we found that the inhibition rate of the sequential treatment (cisplatin →fucoidan) was 50 ∼ 75%. However, the inhibition rate of the sequential treatment, with fucoidan pretreatment, was increased to 75 ∼ 85%.
Source: Cancer Letters - Category: Cancer & Oncology Authors: Hsien-Yeh Hsu, Tung-Yi Lin, Chun-Hao Hu, David Ta Fu Shu, Mei-Kuang Lu Tags: Original Articles Source Type: research